Using urolithin A nanoparticles to treat acute kidney injury
Urolithin A nanoparticle therapy for acute kidney injury
['FUNDING_R01'] · UNIVERSITY OF ALABAMA IN TUSCALOOSA · NIH-11055400
This study is looking at a special treatment using urolithin A, a natural compound that helps protect the kidneys, and testing it in tiny particles to make it work better for people with acute kidney injury.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA IN TUSCALOOSA (nih funded) |
| Locations | 1 site (TUSCALOOSA, UNITED STATES) |
| Trial ID | NIH-11055400 on ClinicalTrials.gov |
What this research studies
This research investigates the use of urolithin A, a compound derived from gut bacteria, encapsulated in nanoparticles to improve its effectiveness in treating acute kidney injury (AKI). The study focuses on enhancing the bioavailability of urolithin A, which has antioxidant and anti-inflammatory properties that may protect the kidneys from damage. By utilizing biodegradable nanoparticles, the research aims to deliver urolithin A more effectively, potentially reducing kidney injury and improving patient outcomes. The approach has shown promising results in animal models, indicating a significant reduction in kidney damage and mortality rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of or currently experiencing acute kidney injury, particularly those undergoing treatments that may exacerbate kidney damage.
Not a fit: Patients with chronic kidney disease or those who do not have acute kidney injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients suffering from acute kidney injury, improving recovery and reducing complications.
How similar studies have performed: Previous studies have shown success with nanoparticle delivery systems for other therapeutic agents, suggesting a promising avenue for this approach in treating acute kidney injury.
Where this research is happening
TUSCALOOSA, UNITED STATES
- UNIVERSITY OF ALABAMA IN TUSCALOOSA — TUSCALOOSA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAJETI, RAVIKUMAR N — UNIVERSITY OF ALABAMA IN TUSCALOOSA
- Study coordinator: MAJETI, RAVIKUMAR N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: acute kidney injury